文献速递艾滋病与性传播感染

重型经治且病毒学抑制的HIV成人患者从复杂方案转换为比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺联合达芦那韦/考比司他两片方案

Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens.
PubMed 文献 · J Antimicrob Chemother · 2023-01-01

多中心前瞻性单臂先导试验纳入63例既往病毒学失败和/或毒性导致复杂方案的重型经治HIV成人,转换至比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺联合达芦那韦/考比司他后,48周意向治疗分析95%病毒载量<50拷贝/mL,符合方案分析100%,3例因毒性停药。

要点

  • 48周病毒载量<50拷贝/mL:意向治疗分析95%,符合方案分析100%。
  • 3例因毒性停药,提示该两片方案总体耐受性良好。
  • 仅第4周估算肾小球滤过率显著下降,可能与肾脏转运体相互作用有关。

核心结论

  • 数据提示比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺联合达芦那韦/考比司他对稳定重型经治HIV成人有效且耐受良好,可能提高便利性并潜在改善长期成功率。

研究设计与样本

  • 多中心、前瞻性、单臂先导临床试验,纳入63例病毒学抑制的HIV成人,既往因病毒学失败和/或毒性使用至少3片、至少3类药物的稳定方案,且无整合酶链转移抑制剂或达芦那韦耐药记录(斯坦福评分≥15分)。
  • 基线扩增HIV-1前病毒DNA并用Illumina测序,22例用UHPLC-MS/MS测定比克替拉韦血浆浓度,主要终点为48周病毒载量<50拷贝/mL(意向治疗分析)。

主要发现

  • 入组63例(92%男性),基线中位CD4计数515 cells/mm3(IQR:334.5-734.5),抗逆转录病毒治疗中位24年(IQR:15.9-27.8),中位药片数4片(范围:3-10)。
  • 基线39例前病毒DNA扩增成功,其中33/39存在耐药突变。
  • 48周病毒载量<50拷贝/mL:意向治疗分析95%,符合方案分析100%;3例因毒性停药。
  • 比克替拉韦血浆浓度轻度升高,估算肾小球滤过率仅在第四周显著下降,可能与肾脏转运体相互作用有关。

关键数值与推荐

  • 主要终点48周病毒载量<50拷贝/mL:意向治疗分析95%,符合方案分析100%。
  • 基线中位CD4计数515 cells/mm3(IQR:334.5-734.5),抗逆转录病毒治疗中位24年(IQR:15.9-27.8),中位药片数4片(范围:3-10)。
  • 3例因毒性停药。

临床怎么用

  • 作者认为比克替拉韦/恩曲他滨/替诺福韦艾拉酚胺联合达芦那韦/考比司他是有效、耐受良好的方案,可能提高便利性并潜在改善稳定重型经治HIV患者的长期成功率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate the efficacy and safety of the two-pill regimen bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat as a switching strategy in heavily treatment-experienced people living with HIV (PLWH). METHODS: Multicentre, prospective, single-arm pilot clinical trial. Participants were virologically suppressed adults receiving a stable antiretroviral regimen of at least three pills from at least three drug families due to previous virological failures and/or toxicities with no documented resistance to integrase strand transfer inhibitors or darunavir (≥15 points, Stanford). Clinical and laboratory assessments were performed at 0, 4, 12, 24, 36 and 48 weeks. HIV-1 proviral DNA was amplified and sequenced by Illumina at baseline. Plasma bictegravir concentrations were determined in 22 patients using UHPLC-MS/MS. The primary study endpoint was viral load (VL)< 50 copies/mL at Week 48 (ITT). RESULTS: We enrolled 63 participants (92% men) with median baseline CD4 count of 515 cells/mm3 (IQR: 334.5-734.5), 24 years on ART (IQR: 15.9-27.8). The median number of pills was 4 (range: 3-10). At baseline, proviral DNA was amplified in 39 participants: 33/39 had resistance mutations. Three participants discontinued owing to toxicity. At 48 weeks, 95% had VL < 50 copies/mL by ITT and 100% by PP analysis. A modest increase was observed in the bictegravir plasma concentration, and a significant decrease in estimated glomerular filtration rate was observed only at Week 4, probably related to interaction with renal transporters. CONCLUSIONS: Our data suggest that BIC/FTC/TAF + darunavir/cobicistat is an effective, well-tolerated regimen that may improve convenience and, potentially, long-term success in stable heavily pre-treated PLWH.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Podzamczer D, Imaz A, Lopez-Lirola A, et al. Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens. J Antimicrob Chemother. 2023. PMID: 37725999. doi:10.1093/jac/dkad285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。